Guyer William 4

What Happened

• William Guyer, Chief Development Officer of Corcept Therapeutics (CORT), exercised 20,000 option shares and sold 20,000 shares on February 3, 2026. He paid $21.65 per share to exercise (total cost $433,000) and sold the shares in the open market at a weighted-average price of $40.87 for total proceeds of $817,334. The exercise-and-sale generated approximately $384,334 in gross proceeds before taxes and fees. A separate derivative line for 20,000 shares at $0.00 reflects the mechanics of the option conversion reported on the Form 4.

Key Details

• Transaction date: 2026-02-03; Form 4 filed 2026-02-05 (period of report 2026-02-03).
• Exercise: 20,000 shares at $21.65/share — $433,000 paid (code M, fully exercisable per footnote F3).
• Sale: 20,000 shares sold in open market at weighted avg $40.87/share — $817,334 proceeds (price range $40.71–$41.2804 per footnote F2).
• Net cash (proceeds minus exercise cost): ~ $384,334 (pre-tax).
• Sale executed under a pre-arranged 10b5-1 plan adopted Nov 27, 2024 (footnote F1).
• The filing notes a power of attorney on file with the SEC (remarks). Post-transaction holdings are not provided in the excerpt.

Context

• This was an exercise-plus-sale (common “exercise and sell” or cash-out) executed under a 10b5-1 plan; such sales are typically pre-arranged and do not necessarily indicate a change in insider sentiment. The derivative/zero-dollar line reflects option conversion mechanics reported on Form 4. This filing appears timely (no late-filing flag).